Diphencyprone and topical tacrolimus as two topical immunotherapeutic modalities. Are they effective in the treatment of alopecia areata among Egyptian patients? A study using CD4, CD8 and MHC II as markers

Journal of Dermatological Treatment

Volumn 22, Issue 1, 2011, Pages 2-10

  Hunter, Nahla ^a   Shaker, Olfat ^a   Marei, Nema ^b  

^a CAIRO UNIVERSITY   (Egypt)

^b CAIRO UNIVERSITY   (Egypt)

Author keywords

Alopecia areata; CD4; CD8; Diphencyprone; MHC II; Tacrolimus

Indexed keywords

BIOCHEMICAL MARKER; CD4 ANTIGEN; CD8 ANTIGEN; DIPHENCYPRONE; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 2; MONOCLONAL ANTIBODY; TACROLIMUS;

ADOLESCENT; ADULT; ALOPECIA AREATA; ANTIGEN EXPRESSION; ARTICLE; CHILD; CLINICAL ARTICLE; CONTROLLED STUDY; DISEASE SEVERITY; DRUG EFFICACY; DRUG RESPONSE; EGYPT; FEMALE; HAIR LOSS; HISTOLOGY; HUMAN; IMMUNOPHENOTYPING; LYMPHOCYTE SUBPOPULATION; MALE; PRIORITY JOURNAL; PROGNOSIS; SCALP; SCHOOL CHILD; SKIN BIOPSY; TREATMENT OUTCOME;

ADMINISTRATION, TOPICAL; ADOLESCENT; ADULT; ALOPECIA AREATA; ANTIBODIES, MONOCLONAL; ANTIGENS, CD4; ANTIGENS, CD8; BIOLOGICAL MARKERS; CHILD; CYCLOPROPANES; EGYPT; FEMALE; HISTOCOMPATIBILITY ANTIGENS CLASS II; HUMANS; IMMUNOHISTOCHEMISTRY; IMMUNOSUPPRESSIVE AGENTS; MALE; SCALP DERMATOSES; T-LYMPHOCYTE SUBSETS; TACROLIMUS; TREATMENT OUTCOME; YOUNG ADULT;

EID: 78650963425     PISSN: 09546634     EISSN: 14711753     Source Type: Journal    
DOI: 10.3109/09546630903410182     Document Type: Article

References (37)

1. Mitchell AJ, Krull EA. Alopecia areata pathogenesis and treatment. J Am Acad Dermatol. 1984;11:763-775.
2. Gilhar A, Kalish RS. Alopecia areata: A tissue specific autoimmune disease of the hair follicle. Autoimmun Rev. 2006;5(1):64-69.
3. Ito T, Ito N, Saatoff M, Hashizume H, Fukimazu H. Maintenance of hair follicle immune privilege is linked to prevention of NK cell attack. J Invest Dermatol. 2008;128(5):1196-1206.
4. Ito T, Aoshima M, Ito N, Uchiyama I. Combination therapy with oral PUVA and corticosteroid for recalcitrant alopecia areata. Arch Dermatol Res. 2009;301:373-380.
5. McElwee K, Spiers E, Oliver R. Partial model for alopecia areata after in vivo depletion of CD4 T cells. Br J Dermatol. 1999;140:432-437.
6. Simonetti O, Lucarini G, Bernardini M, Simoncini C, Biagini G, Offidani A. Expression of vascular endothelial growth factor, apoptosis inhibitors (survivin and p16) and CCL27 in alopecia areata before and after diphencyprone treatment: An immunohistochemical study. Br J Dermatol. 2004;150:940-948.
7. Sehgal V, Srivastava G, Dogra S. Tacrolimus: Approved and unapproved dermatologic indications/uses - Physicians sequential literature survey: Part II. Skinmed. 2008;7:73-78.
8. Avgerinou G, Gregoriou S, Rigopoulas D, Sratigos A, Kalogeromitros D, Katsambas A. Alopecia areata topical immunotherapy with diphencyprone. J Eur Acad Dermatol Venereol. 2008;22:320-323.
9. Madani S, Shapiro J. Alopecia areata update. J Am Acad Dermatol. 2000;42:549-566.
10. Pericin M, Truebe R. Topical immunotherapy of severe alopecia areata with diphencyprone evaluation of 68 cases. Dermatology. 1998;196:418-421.
11. Wiseman MC, Shapiro J, MacDonald N, Lui H. Predictive model for immunotherapy of alopecia areata with diphencyprone. Arch Dermatol. 2001;137:1063-1068.
12. Cotelessa C, Peris K, Caracciolo E, Mordenti C, Chimenti S. The use of topical diphenylcyclopropenone for the treatment of extensive alopecia areata. J Am Acad Dermatol. 2001;44:73-76.
13. McDonaldHull S,Norris JF.Diphencyprone in the treatment of longstandingalopeciaareata.Br JDermatol.1988;119:367-374.
14. Firooz A, Bouzari N, Mojtahed F, Pazoki-Toroudi H, Nassiri-Kashini M, Davoudi M, Dawlati Y. Topical immunotherapy with diphencyprone in the treatment of extensive and or long lasting alopecia areata. J Eur Acad Dermatol Venereol. 2005;19:393-394.
15. Shapiro J, Tan J, Ho V, Abbott F, Tron V. Treatment of chronic severe alopecia areata with topical diphenylcyclopropenone and 5% minoxidil. J Am Acad Dermatol. 1998;29:729-735.
16. Van der Steen P, Happle R. Topical immunotherapy of alopecia areata. Dermatol Clin. 1993;11:619-622.
17. Hull SM, Pepall L, Cunliffe WJ. Alopecia areata in children: Response to treatment with diphencyprone. Br J Dermatol. 1991;125:164-168.
18. Hoffmann R, Happle R. Topical immunotherapy in alopecia areata.What, how and why? Dermatol Clin. 1996;14:739-744.
19. Freyschmidt-Paul P, Hamm H, Happle R, Hoffmann R. Pronounced perifollicular lymphocytic infiltrate in alopecia areata are associated with poor treatment response to diphencyprone. Eur J Dermatol. 1999;9:111-114.
20. Kehren J, Desvignes C, Krasteva M, Ducluzeau M, Assossou O, Horand F, et al. Cytotoxicity is mandatory for CD8 T cell mediated contact hypersensitivity. J Exp Med. 1999;189:779-786.
21. Thein C, Strange P, Hansen ER, Baadsgaard O. Lesional alopecia areata T lymphocytes downregulate epithelial cell proliferation. Arch Dermatol Res. 1997;289:384-388.
22. Tobin D, Gardener S, Lindsey N, Hoffmann R, Happle R. Diphencyprone immunotherapy alters anti-hair follicle antibody status in patients with alopecia areata. Eur J Dermatol. 2002;12:327-334.
23. Freyschmidt-Paul P, Sundberg J, Happle R, Mclwee K, Metz S, Boggers D, et al. Successful treatment of alopecia areata like hair loss with the contact sensitizers quaric acid dibutyl ester in C3H/HEL mice. J Invest Dermatol. 1999;113:61-68.
24. Freyschmidt-Paul P, Hoffmann R, Levin E, Sundberg R, Happle R, Mclwee K. Current and potential agents for the treatment of alopecia areata.Curr PharmDes. 2001;7:213-270.
25. Hoffmann R, Wenzel E, Huth A, Henninger HP, Steen P, Schaufele M, et al. Cytokine mRNA levels in alopecia areata before and after treatment with the contact allergen diphenylcyprone. J Invest Dermatol. 1994;103:530-533.
26. de Waal Malefyt R, Abrams J, Bennet B, Fidget G, de Vries J. Interleukin-10 (IL-10) inhibits cytokine synthesis by human monocytes: An autoregulatory role of IL-10 produced by monocytes. J Exp Med. 1991;174:1209-1220.
27. Seifert M, Sterry L, Effenberger E, Rexin A, Friedrich M, Haeussler-Quade A, et al. The antipsoriatic activity of IL-10 is rather caused by effects on peripheral blood cells than by direct effect on human keratinocytes. Arch Dermatol Res. 2000;292:164-172.
28. Gilhar A, Kam Y, Assy B, Kalish R. Alopecia areata induced in C3H/Hej mice by interferon gamma: Evidence for loss of immune privilege. J Invest Dermatol. 2005;124:288-289.
29. McElwee J, Hoffmann R. Alopecia areata in animal models. Clin Exp Dermatol. 2002;27:410-417.
30. Price V,Willey A, Chen B. Topical tacrolimus in the treatment of alopecia areata. J Am Acad Dermatol. 2005;52:138-139.
31. Feldman K, Kunte C, Wollenberg A, Wolff H. Is topical tacrolimus effective in alopecia areata universalis? Br J Dermatol. 2002;147:1031-1032.
32. Thiers B. Topical tacrolimus: Treatment failure in a patient with alopecia areata. Arch Dermatol. 2000;136:124.
33. Mcelwee K, Rushton D, Trachy R, Oliver R. Topical FK506: A potent immunotherapy for alopecia areata. Studies using the Dundee experimental bald rat model. Br J Dermatol. 1997;137:491-497.
34. McElwee K, Spiers E, Oliver R. Partial model for alopecia areata after in vivo depletion of CD4 cells. Br J Dermatol. 1999;140:432-437.
35. Queille-Roussel C, Paul C, Duteil L. The new topical ascomycin derivative SCZ ASM 981 does not induce skin atrophy when applied to normal skin for 4 weeks: A randomized double blind controlled study. Br J Dermatol. 2001;144:507-513.
36. Sehgal V, Srivastava G, Dogra S. Tacrolimus: Approved and unapproved dermatologic indications/uses - Physicians sequential literature survey; Part II. Skinmed. 2008;7:73-77.
37. Happle R. Topical immunotherapy in alopecia areata. J Invest Dermatol. 1991;96:71S-72S.